Skip to main content
Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

47 views
Download
Pharmaceutical

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Advanced pharmaceutical formulation for targeted therapeutic intervention.

Dosage

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Strength

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Pack Size

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Form

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Source

European Medicines Agency

View Source

Safety Profile

Contraindications

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Side Effects

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Related Clinical Articles

Scan this QR code to access this page quickly on your mobile device.

QR Code